[Prevention of atrial fibrillation by atrial-based pacemaker implantation].
A large number of studies have demonstrated the long term disadvantage of single lead ventricular pacing in sick sinus syndrome. Ventricular pacing mode predicts chronic atrial fibrillation in patients with preimplant paroxysmal atrial fibrillation. The goal of the report was to study the effectiveness of single atrial and dual chamber (atrio-ventricular sequential) pacemaker treatment in the prevention of atrial fibrillation for patients with sick sinus syndrome complicated with paroxysmal atrial fibrillation. In our university hospital 16 atrial based 5 and dual chamber 11 pacemaker were implanted for treatment of patients with sick sinus syndrome (with or without AV conduction disturbances) complicated with paroxysmal atrial fibrillation. The mean age were 61 (24-78), nine males and seven females. Before or during pacemaker implantation sinus node and AV node function analysis, and echocardiography were performed. There were no surgical complications, lead and/or generator failure. All patients had routine follow-up performed at 4 weeks, 3 months, 6 months. Mean follow up was 31 +/- 8 months (range 3 to 93 months). The atrial based and dual chamber pacing were effective in 90% of our cases. In one patient the treatment had to be combined with propafenone. According to our result, the atrial based pacing may be used to reduce the incidence of atrial fibrillation with careful programming of the base atrial pacing rate, and it is associated with lower frequencies of thromboembolic complications and pacemaker syndrome.
Lörincz
I
I
Debreceni Orvostudományi Egyetem, I. sz. Belgyógyászati Klinika.
Vaszily
M
M
Szabó
Z
Z
Horváth
G
G
Kovács
P
P
Polgár
P
P
Karányi
Z
Z
Wórum
F
F
D001145:Arrhythmias, Cardiac / Q000517:prevention & control* / Q000628:therapy; D001281:Atrial Fibrillation / Q000517:prevention & control* / Q000628:therapy; D006801:Humans; D010138:Pacemaker, Artificial; D013614:Tachycardia, Paroxysmal / Q000517:prevention & control / Q000628:therapy; D013923:Thromboembolism / Q000517:prevention & control